Skip to main content

Table 4 Adverse events after cyclophosphamide treatment

From: Cyclophosphamide treatment with a comparison in both pediatric rheumatology and pediatric nephrology practices

 

Pediatric rheumatologists

Pediatric nephrologists

p-value

n = 56 (100%)

n = 31 (100%)

Adverse effects after CYC treatment

   

 Cytopenia

49 (88%)

26 (84%)

0.638

 Nausea

27 (48%)

18 (58%)

0.378

 Liver toxicity

11 (20%)

6 (19%)

0.974

 Hair loss

12 (21%)

15 (48%)

0.009

 Hemorrhagic cystitis

17 (30%)

15 (48%)

0.094

 Allergic reaction

8 (14%)

6 (19%)

0.537

 Dyspnea

4 (7%)

N/A

 

 Infertility

2 (4%)

N/A

 

 Mild infection

25 (45%)

12 (39%)

0.591

 Severe infection

5 (9%)

3 (10%)

0.907

 No adverse effects

1 (2%)

N/A

 

How long after CYC did the infection develop?

   

 1 week

20 (36%)

8 (26%)

0.343

 2 weeks

17 (30%)

8 (26%)

0.653

 1 month

6 (11%)

4 (13%)

0.759

 3 months

N/A

2 (6%)

 

Infections after CYC

   

 Upper respiratory tract infection

31 (55%)

14 (45%)

0.362

 Lower respiratory tract infection

10 (18%)

12 (39%)

0.032

 Herpes simplex infection

7 (13%)

3 (10%)

0.835

 Skin infection

3 (5%)

N/A

 

 Urinary tract infection

4 (7%)

2 (6%)

0.903

 CMV infection

5 (9%)

N/A

 

 Pneumocystis jirovecii infection

2 (4%)

2 (6%)

0.539

 COVID-19 infection

N/A

2 (6%)

 

 Opportunistic fungal infection

3 (5%)

3 (10%)

0.446

 Influenza

3 (5%)

1 (3%)

0.649

  1. CYC: cyclophosphamide; CMV: cytomegalovirus; N/A: not available